Endoscopy 2018; 50(04): S155
DOI: 10.1055/s-0038-1637501
ESGE Days 2018 ePosters
Georg Thieme Verlag KG Stuttgart · New York

REBLEEDING RATE AND RELATED RISK FACTORS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED ENTEROPATHY

J Park
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
JO Kim
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
SR Jeon
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
HG Kim
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
TH Lee
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
JH Cho
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
BM Ko
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
JS Lee
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
,
MS Lee
1   Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea, Republic of
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2018 (online)

Also available ateRef
 

Aims:

Limited evidence is available regarding rebleeding due to non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy. Previous studies have primarily analyzed endoscopic findings. Therefore, there is a need to evaluate the clinical implications for patients. The aim of this study was to evaluate the rebleeding rate and its related risk factors in patients with NSAID-induced enteropathy.

Methods:

Of 402 patients with obscure gastrointestinal bleeding who were evaluated with capsule endoscopy, 49 were diagnosed with NSAID-induced enteropathy. We retrospectively analyzed the clinical characteristics. The Charlson comorbidity index was used to stratify comorbidities. For patients who used additional drugs that influenced their bleeding tendencies, the odds ratio was calculated and used for a quantitative comparison.

Results:

The rebleeding rate in patients with NSAID-induced enteropathy was 20.4% within 23.4 months, on average. Age < 65 years (hazard ratio [HR]: 0.116, 95% confidence interval [CI]: 0.015 – 0.868); use of additional mucoprotective agents (HR: 0.085, 95% CI: 0.010 – 0.717); and discontinuation of NSAIDs after the first bleed (HR: 0.101 95% CI: 0.013 – 0.783) were independently related with rebleeding due to NSAID-induced enteropathy. The underlying comorbidities, drug-related rebleeding risk scores, and therapeutic use of proton pump inhibitors were not significantly different (p = 0.209, 0.212, and 0.720, respectively).

Conclusions:

Approximately one-fifth of patients with NSAID-induced enteropathy showed rebleeding within 2 years. Careful long-term follow-up should be offered to elderly patients with NSAID-induced enteropathy who need continual NSAID treatment.